# US 2003/0069629 A1 · Bioresorbable medical devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069629 A1
- Document ID: US20030069629A1
- Status: Published application
- Kind: A1
- Application number: 10/128,867
- Filed: 2002-04-23
- Published: 2003-04-10
- Earliest claimed: 2001-06-01
- Inventors: Balkrishna S. Jadhav; Robert C. Grant
- Web page: https://patentgrep.com/patent/US20030069629A1

## CPC

- A61F 2/95: Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F 2/90: characterised by a net-like or mesh-like structure
- A61F 2/91: made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F 2/915: with bands having a meander structure, adjacent bands being connected to each other
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/14: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61F 2002/91541: {Adjacent bands are arranged out of phase}
- A61F 2002/91558: {connected peak to peak}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A bio-compatible and bioresorbable medical device is disclosed. Specifically a polymeric stent is disclosed intended to restore or maintain patency following surgical procedures, traumatic injury or stricture formation. The polymeric stent is composed of one or more polymers that is either extruded as a monofilament then woven into a braid-like embodiment, or injection molded or extruded as a tube with fenestrations in the wall. Related methods for controlling the medical devices' in vivo functional life by controlling polymer monomer content and other polymer structural qualities are also provided.

## Claims

### Claim 1

A method for controlling a polymeric stent's in vivo functional life span comprising:
selecting a bioresorbable, biocompatible polymer composition,
determining a monomer content within said bioresorbable, biocompatible polymer composition,
adjusting said monomer content in said bioresorbable, biocompatible polymer to within a predetermined range.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said monomer content is adjusted in said bioresorbable, biocompatible polymer by the addition of monomer to said bioresorbable, biocompatible polymer composition prior to blending or extrusion.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said monomer content in said polymeric composition is adjusted prior to stent formation using a method selected from the group consisting of polymer extrusion pressure, temperature, residence time and combinations thereof.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said selected bioresorbable, biocompatible polymer composition has a high molecular weight (high inherent viscosity).

### Claim 5 (depends on 1)

The method according to claim 1 wherein said polymeric biological stent is made from a method comprising weaving said polymeric stent from polymeric filaments or extruding a polymeric tube and cutting fenestrations into said polymeric tube.

### Claim 6

A method for controlling bioresorbable stent in vivo functional life wherein said stent comprises a polymeric composition having monomer content within a predetermined range comprising:
adjusting said monomer content to within said predetermined range in said polymeric composition prior to stent formation using a method selected from the group consisting of polymer extrusion pressure and temperature, blending polymeric ingredients, having differing monomer content, adding monomer to said polymeric composition and combinations thereof.

### Claim 7 (depends on 6)

The method according to claim 6 wherein said polymeric biological stent is made from a method comprising weaving said polymeric stent from polymeric filaments or extruding a polymeric tube and cutting fenestrations into said polymeric tube.

### Claim 8

A method of producing a bioresorbable, polymeric stent comprising:
providing biocompatible, bioresorbable polymeric monofilaments wherein said polymeric monofilaments comprise a polymeric composition adjusted to have a monomer content within a predetermined range;
braiding said monofilaments into a latticed network, said latticed network having an alternating braiding pattern; and
annealing said latticed structure.

### Claim 9 (depends on 8)

The method according to claim 8 wherein said monomer content in said polymer composition is adjusted prior to stent formation using a method selected from the group consisting of polymer extrusion pressure and temperature and residence time and combinations thereof.

### Claim 10 (depends on 8)

The method according to claim 8 wherein said monomer content in said polymer composition is adjusted in said polymeric monofilament to within a predetermined range through a processes comprising blending polymeric ingredients having differing monomer contents.

### Claim 11 (depends on 8)

The method according to claim 8 wherein said biocompatible, bioresorbable monofilaments are poly-L-lactide monofilaments.

### Claim 12 (depends on 11)

The method according to claim 11 wherein said annealing step further includes heating said latticed structure to 90° C. in an inert atmosphere.

### Claim 13 (depends on 12)

The method according to claim 12 wherein said inert atmosphere is selected from the group consisting of nitrogen, argon, and helium.

### Claim 14 (depends on 12)

The method according to claim 12 wherein said inert atmosphere comprises a high vacuum.

### Claim 15 (depends on 8)

The method according to claim 8 further comprising:
axially compressing said latticed structure by 30% to 60% prior to said annealing step.

### Claim 16 (depends on 11)

The method according to claim 11 wherein said ratio of low molecular weight polymeric sub-units to high molecular weight polymeric molecules is adjusted in said polymer monofilament used to form said polymeric stent prior to stent formation using a method selected from the group consisting of polymer extrusion pressure and temperature, blending polymeric ingredients having differing monomer contents used to form said polymeric material used to form said polymeric biological stents and combinations thereof.

### Claim 17

A method of producing a bioresorbable, polymeric stent comprising:
selecting a bioresorbable, biocompatible polymer composition,
determining a monomer content within said bioresorbable, biocompatible polymer composition,
adjusting said monomer content in said bioresorbable, biocompatible polymer to within a predetermined range,
extruding said polymer composition Into monofilaments,
braiding said monofilaments into a latticed structure, wherein said biocompatible, bioresorbable monofilaments are woven in an alternating braiding pattern; and
annealing said latticed structure in an inert atmosphere wherein said inert atmosphere is selected from the group consisting of nitrogen, argon, helium, and high vacuum.

### Claim 18 (depends on 17)

The method according to claim 17 further comprising:
axially compressing said latticed structure on a mandrel by 30% to 60% prior to said annealing step.

### Claim 19 (depends on 17)

The method according to claim 17 further comprising:
exposing said annealed latticed structure to gamma irradiation.

### Claim 20 (depends on 19)

The method according to claim 19 wherein said latticed structure is exposed to approximately 35 kGy to 75 kGy total dose of gamma irradiation.

### Claim 21

A method of producing a bioresorbable, self-expanding stent comprising:
(a) selecting a high molecular weight poly-L-lactic acid (PLLA) polymeric composition,
(b) determining a monomer content within PLLA;
(c) adjusting said monomer content in said PLLA to within a predetermined range;
(d) extruding said PLLA into monofilaments;
(e) braiding said poly-L-lactide monofilaments into a latticed structure, wherein said poly-L-lactide monofilaments are woven in an alternating under-two-over-two pattern;
(f) axially compressing said latticed structure on a mandrel by 30% to 60%
(g) annealing said latticed structure at approximately 90° C. for at least one hour in an inert atmosphere, wherein said inert atmosphere is selected from the group consisting of nitrogen, argon, helium, and high vacuum; and
(h) exposing said latticed structure to approximately 35 kGy to 75 kGy total dose of gamma irradiation.

### Claim 22

A method of producing a stent comprising:
selecting a bioresorbable, biocompatible polymer composition,
determining a monomer content within said bioresorbable, biocompatible polymer composition,
adjusting said monomer content in said bioresorbable, biocompatible polymer to within a predetermined range,
forming a tubular sheath having fenestrations from said biocompatible, bioresorbable polymer; and
annealing said tubular sheath.

### Claim 23 (depends on 22)

The method according to claim 22 wherein said forming step further comprises injection molding or extruding said tubular sheath.

### Claim 24

The method according to 22 wherein said annealing step further comprises heating said tubular sheath for approximately one to three hours.

### Claim 25 (depends on 22)

The method according to claim 22 wherein said annealing step further includes exposing said tubular sheath to an inert atmosphere inert atmosphere is selected from the group consisting of nitrogen, argon, and helium.

### Claim 26 (depends on 24)

The method according to claim 24 wherein said annealing step further includes exposing said tubular sheath to a high vacuum.

### Claim 27 (depends on 22)

The method according to claim 22 wherein said forming step further comprises laser cutting said fenestrations.

### Claim 28

A method of producing a stent comprising:
selecting a bioresorbable, biocompatible polymer composition,
determining a monomer content within said bioresorbable, biocompatible polymer composition,
adjusting said monomer content in said bioresorbable, biocompatible polymer to within a predetermined range,
forming a tubular sheath from a biocompatible, bioresorbable polymer;
cutting fenestrations into said tubular sheath; and
annealing said tubular sheath for approximately one to three hours in an inert atmosphere.

### Claim 29 (depends on 28)

The method according to claim 28 wherein said annealing step further includes exposing said tubular sheath to nitrogen, argon or helium.

### Claim 30 (depends on 28)

The method according to claim 28 wherein said annealing step further includes exposing said tubular sheath to high vacuum.

### Claim 31

A bioresorbable, self-expanding stent comprising:
a cylindrical sleeve having a first end and a second end;
a latticed network disposed between said first end and said second end of said cylindrical sleeve;
said latticed network formed from approximately forty monofilaments helically wound about a longitudinal axis of said cylindrical sleeve, wherein approximately twenty of said monofilaments are wound in a clockwise direction and approximately twenty said monofilaments are wound in a counter-clockwise direction, wherein said approximately forty monofilaments are braided in an alternating under-two-over-two braid pattern; and
said plurality of braided monofilaments comprises a PLLA composition wherein said PLLA composition has a monomer content adjusted such that said PLLA composition has a controllable in vivo lifetime.
